Published in Stem Cells Dev on October 01, 2009
Mesenchymal stem cells for the treatment of neurodegenerative disease. Regen Med (2010) 1.89
Neurodegeneration in a transgenic mouse model of multiple system atrophy is associated with altered expression of oligodendroglial-derived neurotrophic factors. J Neurosci (2010) 1.20
Intravenous administration of mesenchymal stem cells exerts therapeutic effects on parkinsonian model of rats: focusing on neuroprotective effects of stromal cell-derived factor-1alpha. BMC Neurosci (2010) 1.11
7,8-Dihydroxyflavone, a small molecule TrkB agonist, improves spatial memory and increases thin spine density in a mouse model of Alzheimer disease-like neuronal loss. PLoS One (2014) 1.01
Pathogenesis-targeted, disease-modifying therapies in Parkinson disease. Neurotherapeutics (2014) 0.92
Autologous mesenchymal stem cell therapy for progressive supranuclear palsy: translation into a phase I controlled, randomized clinical study. J Transl Med (2014) 0.90
Parkinson's disease and mesenchymal stem cells: potential for cell-based therapy. Parkinsons Dis (2012) 0.89
Mesenchymal stem cells secretome as a modulator of the neurogenic niche: basic insights and therapeutic opportunities. Front Cell Neurosci (2015) 0.86
Use of genetically modified mesenchymal stem cells to treat neurodegenerative diseases. Int J Mol Sci (2014) 0.84
Safety of repeated transplantations of neurotrophic factors-secreting human mesenchymal stromal stem cells. Clin Transl Med (2014) 0.83
Contamination of mesenchymal stem-cells with fibroblasts accelerates neurodegeneration in an experimental model of Parkinson's disease. Stem Cell Rev (2011) 0.83
From molecular to nanotechnology strategies for delivery of neurotrophins: emphasis on brain-derived neurotrophic factor (BDNF). Pharmaceutics (2013) 0.83
Delayed transplantation of precursor cell-derived astrocytes provides multiple benefits in a rat model of Parkinsons. EMBO Mol Med (2014) 0.82
Stem cell therapy for glaucoma: possibilities and practicalities. Expert Rev Ophthalmol (2011) 0.81
Intrastriatal transplantation of neurotrophic factor-secreting human mesenchymal stem cells improves motor function and extends survival in R6/2 transgenic mouse model for Huntington's disease. PLoS Curr (2012) 0.81
Intracerebral adult stem cells transplantation increases brain-derived neurotrophic factor levels and protects against phencyclidine-induced social deficit in mice. Transl Psychiatry (2011) 0.81
Intracarotid Infusion of Mesenchymal Stem Cells in an Animal Model of Parkinson's Disease, Focusing on Cell Distribution and Neuroprotective and Behavioral Effects. Stem Cells Transl Med (2015) 0.80
Mitochondrial function in human neuroblastoma cells is up-regulated and protected by NQO1, a plasma membrane redox enzyme. PLoS One (2013) 0.80
Current perspective of neuroprotection and glaucoma. Clin Ophthalmol (2015) 0.80
Prospect of cell therapy for Parkinson's disease. Anat Cell Biol (2011) 0.79
Astrocyte-like cells derived from human oral mucosa stem cells provide neuroprotection in vitro and in vivo. Stem Cells Transl Med (2014) 0.78
Directed differentiation of postnatal hippocampal neural stem cells generates nuclear receptor related‑1 protein‑ and tyrosine hydroxylase‑expressing cells. Mol Med Rep (2016) 0.78
The plasma membrane redox enzyme NQO1 sustains cellular energetics and protects human neuroblastoma cells against metabolic and proteotoxic stress. Age (Dordr) (2011) 0.77
Therapeutics with SPION-labeled stem cells for the main diseases related to brain aging: a systematic review. Int J Nanomedicine (2014) 0.76
Cell based therapy in Parkinsonism. Transl Neurodegener (2013) 0.76
A double-blind, delayed-start trial of rasagiline in Parkinson's disease. N Engl J Med (2009) 5.81
Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma. J Natl Cancer Inst (2003) 5.64
Donor-derived brain tumor following neural stem cell transplantation in an ataxia telangiectasia patient. PLoS Med (2009) 5.50
BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer. J Clin Endocrinol Metab (2005) 4.39
VPS35 mutations in Parkinson disease. Am J Hum Genet (2011) 4.16
Levodopa in the treatment of Parkinson's disease: current controversies. Mov Disord (2004) 2.90
The natural history of multiple system atrophy: a prospective European cohort study. Lancet Neurol (2013) 2.65
The Human MitoChip: a high-throughput sequencing microarray for mitochondrial mutation detection. Genome Res (2004) 2.54
DeltaNp63alpha and TAp63alpha regulate transcription of genes with distinct biological functions in cancer and development. Cancer Res (2003) 2.46
The role of oxidative stress in the pathogenesis of multiple sclerosis: the need for effective antioxidant therapy. J Neurol (2004) 2.40
Use of metal oxide nanoparticle band gap to develop a predictive paradigm for oxidative stress and acute pulmonary inflammation. ACS Nano (2012) 2.35
Protein corona fingerprinting predicts the cellular interaction of gold and silver nanoparticles. ACS Nano (2014) 2.17
Magnetic resonance imaging by synergistic diffusion-diffraction patterns. Phys Rev Lett (2012) 2.02
A coding VKORC1 Asp36Tyr polymorphism predisposes to warfarin resistance. Blood (2006) 1.94
Validation of the freezing of gait questionnaire in patients with Parkinson's disease. Mov Disord (2009) 1.90
Generation of insulin-producing cells from human bone marrow mesenchymal stem cells by genetic manipulation. Stem Cells (2007) 1.85
Antioxidant therapy in acute central nervous system injury: current state. Pharmacol Rev (2002) 1.76
Bax ablation protects against myocardial ischemia-reperfusion injury in transgenic mice. Am J Physiol Heart Circ Physiol (2003) 1.75
Handedness as a predictor of side of onset of Parkinson's disease. Parkinsonism Relat Disord (2008) 1.74
Use of a high-throughput screening approach coupled with in vivo zebrafish embryo screening to develop hazard ranking for engineered nanomaterials. ACS Nano (2011) 1.68
A double-blind, delayed-start trial of rasagiline in Parkinson's disease (the ADAGIO study): prespecified and post-hoc analyses of the need for additional therapies, changes in UPDRS scores, and non-motor outcomes. Lancet Neurol (2011) 1.68
Electrophile and oxidant damage of mitochondrial DNA leading to rapid evolution of homoplasmic mutations. Proc Natl Acad Sci U S A (2003) 1.66
Association of aberrant methylation of tumor suppressor genes with tumor aggressiveness and BRAF mutation in papillary thyroid cancer. Int J Cancer (2006) 1.56
Lesions outside the CNS in Parkinson's disease. Mov Disord (2009) 1.55
The mystery of motor asymmetry in Parkinson's disease. Lancet Neurol (2006) 1.55
Chronic cholinergic imbalances promote brain diffusion and transport abnormalities. FASEB J (2005) 1.50
Erythropoietin delays disease onset in an amyotrophic lateral sclerosis model. Exp Neurol (2006) 1.47
Measuring small compartments with relatively weak gradients by angular double-pulsed-field-gradient NMR. Magn Reson Imaging (2012) 1.47
The "dying-back" phenomenon of motor neurons in ALS. J Mol Neurosci (2010) 1.45
The hyperperfusion syndrome: an under-recognized complication of carotid endarterectomy. Isr Med Assoc J (2004) 1.40
Solitary bone metastasis of renal cell carcinoma treated with limb-sparing surgery followed by radiotherapy. Isr Med Assoc J (2002) 1.39
Classification NanoSAR development for cytotoxicity of metal oxide nanoparticles. Small (2011) 1.39
Preoperative radio-chemotherapy treatment in locally advanced rectal carcinoma. Results of 8-year follow-up. Onkologie (2005) 1.39
Normal white matter development from infancy to adulthood: comparing diffusion tensor and high b value diffusion weighted MR images. J Magn Reson Imaging (2005) 1.38
Early occurrence of RASSF1A hypermethylation and its mutual exclusion with BRAF mutation in thyroid tumorigenesis. Cancer Res (2004) 1.35
Promoter hypermethylation as an independent prognostic factor for relapse in patients with prostate cancer following radical prostatectomy. Clin Cancer Res (2005) 1.30
BRAF mutations in anaplastic thyroid carcinoma: implications for tumor origin, diagnosis and treatment. Mod Pathol (2004) 1.27
Oligodendrocyte dysfunction after induction of experimental anterior optic nerve ischemia. Invest Ophthalmol Vis Sci (2005) 1.26
Mutant and wild-type alpha-synuclein interact with mitochondrial cytochrome C oxidase. J Mol Neurosci (2002) 1.25
The etiopathogenesis of Parkinson disease and suggestions for future research. Part I. J Neuropathol Exp Neurol (2007) 1.21
A general framework to quantify the effect of restricted diffusion on the NMR signal with applications to double pulsed field gradient NMR experiments. J Chem Phys (2009) 1.20
Mitochondrial DNA content increase in response to cigarette smoking. Cancer Epidemiol Biomarkers Prev (2006) 1.20
Methylation of the thyroid-stimulating hormone receptor gene in epithelial thyroid tumors: a marker of malignancy and a cause of gene silencing. Cancer Res (2003) 1.20
Clinicogenetic study of mutations in LRRK2 exon 41 in Parkinson's disease patients from 18 countries. Mov Disord (2006) 1.20
The CONNECT project: Combining macro- and micro-structure. Neuroimage (2013) 1.19
The effect of rotational angle and experimental parameters on the diffraction patterns and micro-structural information obtained from q-space diffusion NMR: implication for diffusion in white matter fibers. J Magn Reson (2004) 1.18
Intravitreal injections of neurotrophic factors secreting mesenchymal stem cells are neuroprotective in rat eyes following optic nerve transection. Invest Ophthalmol Vis Sci (2010) 1.18
Human mesenchymal stem cells express neural genes, suggesting a neural predisposition. Stem Cells Dev (2006) 1.17
Epigenetic inheritance of DNA methylation limits activation-induced expression of FOXP3 in conventional human CD25-CD4+ T cells. Int Immunol (2008) 1.16
[123I]-FP/CIT SPECT imaging for distinguishing drug-induced parkinsonism from Parkinson's disease. Mov Disord (2006) 1.14
CDC91L1 (PIG-U) is a newly discovered oncogene in human bladder cancer. Nat Med (2004) 1.14
BRCA germline mutations in Jewish women with uterine serous papillary carcinoma. Gynecol Oncol (2004) 1.14
The effect of the diffusion time and pulse gradient duration ratio on the diffraction pattern and the structural information estimated from q-space diffusion MR: experiments and simulations. J Magn Reson (2008) 1.14
Toxicity mechanisms in Escherichia coli vary for silver nanoparticles and differ from ionic silver. ACS Nano (2013) 1.13
Bone-marrow-derived mesenchymal stem cell therapy for neurodegenerative diseases. Expert Opin Biol Ther (2009) 1.13
Intravenous immune globulin in autoimmune and inflammatory diseases. N Engl J Med (2013) 1.11
Post-traumatic stress disorder and quality of life in long-term survivors of Hodgkin's disease and non-Hodgkin's lymphoma in Israel. Leuk Lymphoma (2003) 1.11
Self-organizing map analysis of toxicity-related cell signaling pathways for metal and metal oxide nanoparticles. Environ Sci Technol (2011) 1.11
DJ-1 protects against dopamine toxicity. J Neural Transm (Vienna) (2008) 1.11
Sequence variants in HTRA1 and LOC387715/ARMS2 and phenotype and response to photodynamic therapy in neovascular age-related macular degeneration in populations from Israel. Mol Vis (2008) 1.10
White matter changes in multiple sclerosis: correlation of q-space diffusion MRI and 1H MRS. Magn Reson Imaging (2005) 1.09
A new MALDI-TOF-based assay for monitoring JAK2 V617F mutation level in patients undergoing allogeneic stem cell transplantation (allo SCT) for classic myeloproliferative disorders (MPD). Leuk Res (2007) 1.09
Oxidative insults induce DJ-1 upregulation and redistribution: implications for neuroprotection. Neurotoxicology (2008) 1.07
Introducing transcription factors to multipotent mesenchymal stem cells: making transdifferentiation possible. Stem Cells (2009) 1.07
Apoptosis and Parkinson's disease. Prog Neuropsychopharmacol Biol Psychiatry (2003) 1.06
Measuring small compartmental dimensions with low-q angular double-PGSE NMR: The effect of experimental parameters on signal decay. J Magn Reson (2009) 1.05
The University of California Center for the Environmental Implications of Nanotechnology. Environ Sci Technol (2009) 1.05
Self-recognition, structure, stability, and guest affinity of pyrogallol[4]arene and resorcin[4]arene capsules in solution. J Am Chem Soc (2004) 1.04
Detecting cervical cancer by quantitative promoter hypermethylation assay on cervical scrapings: a feasibility study. Mol Cancer Res (2004) 1.04
Microsphere-induced embolic stroke: an MRI study. Magn Reson Med (2004) 1.03
Induction of human mesenchymal stem cells into dopamine-producing cells with different differentiation protocols. Stem Cells Dev (2008) 1.01
Molecular mechanisms of selective dopaminergic neuronal death in Parkinson's disease. Trends Mol Med (2003) 1.00
From single-pulsed field gradient to double-pulsed field gradient MR: gleaning new microstructural information and developing new forms of contrast in MRI. NMR Biomed (2010) 1.00
A low molecular weight copper chelator crosses the blood-brain barrier and attenuates experimental autoimmune encephalomyelitis. J Neurochem (2004) 1.00
Detection of LOH and mitochondrial DNA alterations in ductal lavage and nipple aspirate fluids from hngh-risk patients. Breast Cancer Res Treat (2004) 0.99